JP Morgan analyst Jeffrey Zekauskas upgraded H.B. Fuller to Overweight from Neutral, signaling increased confidence in the company's stock performance. The firm raised its price target for the company to $67 from the previous $58.

Rating and Target Changes

The upgrade reflects a revised outlook on H.B. Fuller's potential. The following table summarizes the changes:

The new price target represents a significant adjustment from the prior estimate.

H.B. Fuller Company has announced a recommended cash offer to acquire Advanced Medical Solutions Group plc for £715 million, aiming to expand its presence in high-growth medical segments and accelerate its path to achieving greater than 20% EBITDA margins. The transaction, which values the target at a pre-synergy EBITDA multiple of 12.9x, is expected to close by the end of the calendar year subject to regulatory approvals. H.B. Fuller shares traded lower in Thursday’s premarket session as investors weighed the offer alongside second-quarter results that beat estimates and raised guidance.

Strategic Rationale

The acquisition is designed to extend H.B. Fuller’s capabilities in tissue bonding adhesives, tapes, dressings, and formulated biosurgicals. By integrating Advanced Medical Solutions, the company anticipates its total addressable market will increase by $15 billion to $95 billion. The deal is also expected to drive immediate cross-selling opportunities through Advanced Medical Solutions’ pan-European salesforce and H.B. Fuller’s U.S. infrastructure.

Financial Synergies and Margins

H.B. Fuller projects the transaction will generate approximately $55 million, or £41 million, in combined run-rate revenue and cost synergies by 2031. These synergies will stem from the elimination of public company costs, rationalization of overlapping expenses, and sourcing savings. The company also expects the acquisition to increase annual revenues by approximately $300 million and contribute to a positive mix shift, supporting its long-term target of 5% annual constant currency revenue growth.

Transaction Structure

Each eligible shareholder of Advanced Medical Solutions will receive £2.85 per share in cash. The acquisition will be fully financed through 100% committed financing. H.B. Fuller intends to rapidly deleverage to a target net debt-to-EBITDA ratio of 2.5x to 3x within two years of the transaction's completion. The deal will establish a new global business unit accounting for approximately 10% of the combined company’s revenues and EBITDA.

Q2 FY26 Performance

H.B. Fuller reported net revenue of $950.3 million for the second quarter of fiscal 2026, an increase of 5.8% year-over-year, surpassing the $924.8 million estimate. Organic revenue grew 2.6%, with pricing gains offsetting a slight decline in volume. Net income reached $68 million. Adjusted EBITDA rose 9% to $181 million, and adjusted diluted EPS increased 19% to $1.41, exceeding the $1.40 estimate. Adjusted gross margin improved by 200 basis points to 34.2%, primarily due to effective pricing and restructuring savings.

Cash Flow, Debt, and Guidance

Operating cash flow reached a record $121 million for the second quarter, up approximately 10% year-over-year. The company also repurchased 750,000 shares during the quarter. H.B. Fuller ended the quarter with cash and cash equivalents of $114.10 million. Net debt was $1.958 billion, down $58 million year-on-year, while net debt-to-adjusted EBITDA improved to 3.1x from 3.4x. For fiscal 2026, the company raised its adjusted EPS guidance to $4.60–$4.90 from $4.55–$4.90.

Key Transaction Metrics

Integration and Operational Benefits

The combined entity will leverage Advanced Medical Solutions’ dedicated R&D team of over 75 individuals and its manufacturing base across the UK, Germany, France, the Netherlands, Thailand, and India. H.B. Fuller highlighted its track record of mergers and acquisitions, noting that since 2023, it has acquired and integrated 11 companies, resulting in a 55% increase in EBITDA and an expansion of EBITDA margins by over 1,000 basis points across that portfolio.